Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
January 11, 2022
The Biostage Chronicles: dispose and disregard, fit for the barrel
December 4, 2021
RegMed Investors (RMi): The week in review …
October 30, 2021
The Biostage (BSTG) Chronicles: what’s there to invest in?
September 23, 2021
Q2/21 Earnings - (LPS - loss-per-share) Results
August 20, 2021
The Biostage (BSTG) Chronicles: Facts from filed 10-Q
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors